How are organizations balancing cost with regulatory, supply chain, and reputational risk when selecting partners or sites?
In a Pharma's Almanac industry roundtable on balancing cost with regulatory, supply chain, and reputational risk in partner selection, Jimin Han, Director of ESG at Samsung Biologics, shares how organizations are moving beyond cost-based sourcing toward risk-adjusted models. He highlights the growing importance of structured due diligence — assessing a supplier's ESG maturity, labor practices, environmental track record, and raw-material traceability — as key to resilience, regulatory readiness, and long-term client trust.
Discover how Samsung Biologics is embedding excellence across its global supply chain.
In a Pharma's Almanac industry roundtable on balancing cost with regulatory, supply chain, and reputational risk in partner selection, Jimin Han, Director of ESG at Samsung Biologics, shares how organizations are moving beyond cost-based sourcing toward risk-adjusted models. He highlights the growing importance of structured due diligence — assessing a supplier's ESG maturity, labor practices, environmental track record, and raw-material traceability — as key to resilience, regulatory readiness, and long-term client trust.
Discover how Samsung Biologics is embedding excellence across its global supply chain.
Share article
Related Content